renal disease at baseline and with consecutive mGFR values (!3) were included. GFR was measured by one sample 51 Cr-ethylenendiaminetetra acetic acid clearance. RESULTS: Fifty-two patients (62% female) with consecutive mGFR values (n¼841) over a median observation time of 7 years [range 1-13] were evaluated. During followup median blood pressure remained within normal limits (<140/90 mmHg), all plasma-globotriaosylceramide levels normalised, and median urine protein excretion did not worsen. Average baseline mGFR was 9063 ml/min/1.73m 2 (6standard error) and rate of renal function loss was 0.960.2 ml/min/1.73m 2 /year. mGFR was compared to a cohort of renal healthy subjects and adjusted to age, giving a Z-score of Ä0.860.2 standard deviation (SDS) scores with a slope of Ä0.0360.01 SDS/year (p¼ 0.099). In age-adjusted analyses, no differences between genders were found. Age-grouping of age-adjusted data showed an exaggerated rate of renal function loss with age in the FD patients compared to the renal healthy subjects. High urine albumin-creatinine-ratio (>300 mg/g) was associated with renal function loss, independent of baseline mGFR, age and gender. CONCLUSIONS: Well-treated ERT receiving FD patients does not have a faster attrition of renal function than renal healthy, but show an exaggerated rate of renal function loss with age independent of gender. High urine albumin-creatinine-ratio (300 mg/g) seems to be an early marker of renal function decline. We suggest cautious interpretation of non-age-adjusted or non-age-grouped data. 
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INTRODUCTION AND AIMS:
Polycystic kidney disease (PKD) comprises a group of monogenic disorders that result in renal cyst development. In this study, the strategies and clinical outcome of a large cohort of preimplantation genetic testing (PGT) cycles for PKD performed at the Centre for Medical Genetics of the Universitair Ziekenhuis Brussel between 2005 and 2016 are reported. As males affected with autosomal dominant polycystic kidney disease (ADPKD) may present with reproductive system abnormalities and infertility, the clinical outcome was compared between couples with the female partner affected with ADPKD and couples with the male partner affected with ADPKD. METHODS: Between 2005 and 2016, 16 single-cell clinical tests for PKD based on multiplex polymerase chain reaction of short tandem repeat markers, with or without a specific mutation, were developed and applied for 91 PGT cycles for 43 couples (33 couples for polycystic kidney disease 1 (PKD1), 2 couples for polycystic kidney disease 2 (PKD2) and 8 couples for autosomal recessive polycystic kidney disease (ARPKD)). In 18 couples, the male partner was affected with ADPKD (¼ Group A) and 12 of them had a documented infertility status (7 with oligoasthenoteratozoospermia (OAT), 3 with obstructive azoospermia and 2 with azoospermia). Group A underwent 52 cycles to oocyte retrieval (OR). For 18 other couples, the female partner was affected with ADPKD (¼ Group B) and 4 male partners from this group had a documented history of infertility (3 with OAT, 1 with asthenozoospermia). This group underwent 31 cycles to OR. RESULTS: Blastomere biopsy was performed on 584 cleavage stage embryos. Genetic analysis resulted in 545 embryos (93.3%) with a diagnosis of which 215 (36.8%) were genetically transferable. Transfer of 74 embryos in 53 fresh cycles resulted in a live birth delivery rate of 37.7% per embryo transfer (ET) with 18 singleton and 2 twin live births. Transfer of 34 cryopreserved embryos in 33 frozen-thawed embryo transfer (FET) cycles resulted in a live birth delivery rate of 39.4% per FET with 13 singleton live births and 1 ongoing pregnancy. Thirty cryopreserved embryos still remain available for transfer. The observed cumulative delivery rate was 57.8% per couple after five treatment cycles. The clinical pregnancy rate per ET (fresh þ frozen; 45.9% in group A vs 60.0% in group B, P < 0.05) and the live birth delivery rate per ET (fresh þ frozen; 27.0% in group A vs 42.9% in group B, P < 0.05) was significantly lower for couples with the male partner affected with ADPKD compared with couples with the female partner affected with ADPKD. However, a multivariate logistic regression analysis showed that only the female age, which is a well-established determinant factor for treatment outcome, was associated with live birth delivery rate (OR 0.87; 95% CI 0.77-0.99; P ¼ 0.032). CONCLUSIONS: This study shows that PGT for PKD performed in our centre offers good reproductive outcomes from both fresh and frozen embryo transfers. Our results can be a valuable tool for counselling PKD patients about their reproductive options. Males affected with ADPKD who suffer from infertility should be advised to seek treatment on time to improve their chances of conceiving a child. 
SP020 FACTORS THAT CORRELATE WITH THE SEVERITY OF RENAL INVOLVEMENT IN PATIENTS WITH FABRY DISEASE

METHODS:
We assessed renal function using serum creatinine and cystatin C, albuminuria and proteinuria. Chronic kidney disease was defined as eGFR <60 mL/min/1.73 m2 and/or urinary albumin/creatinine rate ! 30mg/g. Kidney biopsy was performed in selected patients for diagnostic and evaluation of disease extension. Renal biopsy specimens were analyzed in light microscopy, immunofluorescence and electron microscopy. Echocardiographic evaluation was performed in order to evaluate left ventricular volumes at end-diastole and end-systole, left ventricular function and left ventricular mass (LVM). LVM was indexed to body surface area to obtain the LVM index (LVMI). Statistical analysis was performed using IBM SPSS Statistics Version 21. RESULTS: Between March 2015 and December 2017 we examined 26 patients (mean age, 40.2 years; range, 15-73 years), 14 male and 12 female, 19 patients (73%) showed renal manifestations of Fabry disease. 13 patients (80%) presented eGFR < 60 ml/min/ 1.73 m2. Two patients presented with end stage renal disease at a mean age of 27 years and had received a renal transplant. Proteinuria was present in 17 patients (65%), and one patient had nephrotic proteinuria. Nine patients (34.6%) performed kidney biopsy. 16 patients (61.5%) had cardiac involvement and 21 patients (80.7%) presented neurologic manifestations. Only eight patients received enzyme replacement therapy (ERT) at first evaluation in our clinic. After the complete evaluation of Fabry organ involvement, ERT was initiated in another 10 patients. The result of kidney biopsy contributed decisively to the therapeutic decision. The severity of renal involvement in patients with FD has been correlated with the age of diagnosis of Fabry disease (p¼0.04), elevated serum uric acid (p¼0.0001), proteinuria (p¼0.014), iPTH (p¼0.001), increased LVMI (p¼0.036), the presence of arterial hypertension (p¼0.006), and stroke history (p¼0.04).
CONCLUSIONS: Our experience showed that kidney biopsy is an important tool to assess the kidney involvement and to establish the indication for initiating ERT. In conclusion, besides increasing age at diagnosis, the severity of renal involvement was associated with the severity of proteinuria, hypertension, increased LVMI and stroke history. This cross-sectional study that enrolled total 1148 patients, from January 2013 to June 2017. All recruited patients subjected to meticulous related history in particular family history of renal disease and clinical examination and perform routine investigations, nerve conduction study, slit lamb examination, electrocardiography, and enzyme assay alpha-galactosidase A. Lysosomal enzyme activity assay alpha-galactosidase A of blood spots -using tandem mass spectrometry. RESULTS: The total patients with Fabry's disease are 17 where 16 male, 1 female.One patient (5.9% of total Fabry' cases) less than 10 years old , 12 (70.6% of total Fabry' cases) patients with Fabry's disease among age group from 10-30 years old , 3 (17.6% of total Fabry' cases) patients among age group from 31-50 years and one patient (5.9% of total Fabry' cases) with his age above 50 years old , is statistically significant (p¼0.003).The renal involvement includes 14 patients (82.3% of total Fabry' cases), is statistically significant (p¼0.003). CONCLUSIONS: Screening and early diagnosis of all patients with positive or suspected family history of renal disease SP023 PAX2 VARIANT ASSOCIATED WITH BILATERAL KIDNEY AGENESIS
Maria Rasmussen
INTRODUCTION AND AIMS: Variants in PAX2 have previously been associated with renal coloboma syndrome, isolated congenital anomalies of the kidney and urinary tract (CAKUT), and focal segmental glomerulosclerosis. However, up to now, variants in PAX2 have not been associated with the most severe form of CAKUT, namely bilateral kidney agenesis. Here, we present genetic data from a family revealing that PAX2 not only plays a role in a diverse array of kidney disease, but also in bilateral kidney agenesis. METHODS: Post mortem examination was performed on a 15þ2 fetus following intrauterine demise. DNA extracted from fetal tissue was analyzed using array comparative genomic hybridization. A CAKUT gene panel including the genes BMP7, CDC5L, CHD1L, EYA1, FRAS1, FREM1, FREM2, GATA3, GREB1L, GREM1, GRIP1, HNF1B, ITGA8, PAX2, RET, ROBO2, SALL1, SIX2, SIX5, and TBX18 was examined for disease-associated variants using next generation sequencing. Subsequently, candidate variants were assessed for segregation with kidney phenotypes in the family under study. RESULTS: Post mortem examination of the fetus revealed isolated bilateral kidney agenesis. Array comparative genomic hybridization was normal. The CAKUT gene panel analysis identified the heterozygous PAX2 missense variant c.68T>C (p. (Leu23Pro)). No other candidate variants were identified. The c.68T>C PAX2 variant has not previously been associated with disease, nor has it been reported in variant frequency databases. Prediction software suggests the variant to be pathogenic, and missense variants in the two downstream codons were previously reported as pathogenic. The variant was identified in all affected family members for which DNA was available (see Figure 1) . The kidney phenotypes seen in the family were remarkably heterogeneous, including bilateral kidney agenesis, minimal change nephropathy, ureteropelvic junction obstruction, and bilateral kidney hypoplasia with end stage renal failure in early adult life or with only moderate chronic kidney failure in late adult life. CONCLUSIONS: In conclusion, PAX2 variants can present with broad intrafamilial disease variability. Here we present for the first time a PAX2 variant associated with bilateral kidney agenesis.
